StockData
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc (MREO) stock

MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 1/30
$0.26−0.02 (-5.45%)

Close on Nov 20, 2026Market cap $41.52MP/E –Yield –

Mereo BioPharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Mereo BioPharma's revenue for the twelve months ending Dec 31, 2025 was $500.00K. For fiscal 2025 it was $500.00K.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$500.00K–
FY2024Dec 31, 2024$0-100.0%
FY2023Dec 31, 2023$10.00M–
FY2022Dec 31, 2022$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$800.00K+60.0%
Q2 FY2026Jun 30, 2026$0–
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$500.00K–
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0–
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$0–
Q4 FY2023Dec 31, 2023$1.00M–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$9.00M–
Q1 FY2023Mar 31, 2023$0–

More Mereo BioPharma figures

See a number that looks wrong?